Company Profile
Updated: 17-JUN-09Icam Proprietary Ltd.
International Private company
PO Box 416, North Sydney, 2059, Australia
()61 2 9957 4477, 61 2 9957 6206 fax, http://www.ozemail.com.au/~catalyst
Primary SIC: Miscellaneous Publishing, Primary NAICS: Database and Directory Publishers
Description: Manufacturing: Icam is a provider of interactive multimedia products in Australia. The company specialises in communications for training, marketing and presentation purposes. It offers local production costs with world class interactive multimedia for multi-national clients.
View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!
MorphoSys Provides Update on MOR102 Program in Psoriasis.
PrimeZone Media Network; 4/28/2005; 1356 words; ...IgG4 antibody against ICAM-1, showed clear evidence...from our portfolio of proprietary drug candidates. Over...1992, the Company's proprietary Human Combinatorial Antibody...USA), ProChon Biotech Ltd. (Rehovot/Israel...Germany) and Xoma Ltd. (Berkeley, California...
MorphoSys and Boehringer Ingelheim Start New Antibody Program.
PR Newswire; 8/16/2004; 1520 words; ...this antibody using its proprietary HuCAL GOLD(R) technology...against a target molecule, ICAM-1. ICAM-1 is the basis for MorphoSys...USA), ProChon Biotech Ltd. (Rehovot/Israel...Berlin/Germany) and Xoma Ltd. (Berkeley, California...
MorphoSys and Boehringer Ingelheim start new antibody program.
BIOTECH Patent News; 8/1/2004; 1375 words; ...this antibody using its proprietary HuCAL GOLD technology...against a target molecule, ICAM-1. ICAM-1 is the basis for MorphoSys...USA), ProChon Biotech Ltd. (Rehovot/Israel...Berlin/Germany) and Xoma Ltd. (Berkeley, California...
Therion Biologics Corporation Initiates Phase III Clinical Trial With PANVAC(TM)-VF In Advanced Pancreatic Cancer.
PR Newswire; 6/21/2004; 1277 words; ...vaccine also incorporates TRICOM(TM), Therion's proprietary triad of costimulatory molecules (B7.1, ICAM-1 and LFA-3), designed to enhance and sustain...cancer with its strategic partner, Aventis Pasteur, Ltd. Through Therion's
Therion Biologics obtains rights to Biogen Idec LFA-3.
BIOTECH Patent News; 1/1/2004; 979 words; ...integral component ofTherion's proprietary lead cancer vaccine candidates...property portfolio strengthens our proprietary position as we advance our...co-stimulatory molecules, ICAM-1, B7.1 and LFA-3...institutions and Aventis Pasteur, Ltd., which is developing ALVAC...
Why Purchase This Company Profile?
- Sales prospecting
- Competitive analysis
- Vendor & supplier evaluation
- Customer evaluation and analysis
- Strategic planning